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A B S T R A C T
Key events occurring during the bone healing include well-orchestrated and complex interactions
between immune cells, multipotential stromal cells (MSCs), osteoblasts and osteoclasts. Through three
overlapping phases of this physiological process, innate and adaptive immune cells, cytokines and
chemokines have a signiﬁcant role to play. The aim of the escalating immune response is to achieve an
osseous healing in the shortest time and with the least complications facilitating the restoration of
function. The uninterrupted progression of these biological events in conjunction with a favourable
mechanical environment (stable fracture ﬁxation) remains the hallmark of successful fracture healing.
When failure occurs, either the biological environment or themechanical one could have been disrupted.
Not infrequently bothmay be compromised. Consequently, regenerative treatments involving the use of
bone autograft, allograft or synthetic matrices supplemented with MSCs are increasingly used. A better
understanding of the bone biology and osteoimmunology can help to improve these evolving cell-
therapy based strategies. Herein, an up to date status of the role of immune cells during the different
phases of bone healing is presented. Additionally, the known and yet to know events about immune cell
interactions with MSCs and osteoblasts and osteoclasts and the therapeutic implications are being
discussed.
 2016 Published by Elsevier Ltd.
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Introduction
The interaction betweenbone cells, inﬂammatorymediators and
constituents of the immune system involved in bone repair,
continue to be of great scientiﬁc interest to researchers and
clinicians [1–12]. Investigation of the critical role of immune cells
during the bone healing is ongoing. Depletion of T- and B-
lymphocytes is associated with impairment in bone mineralisation
andmaturation of osteoblasts with delayed repair and remodelling
phases and delayed healing as demonstrated in experimental
models [13,14]. Additionally, Cho et al. demonstrated that resident
macrophages (osteal) are signiﬁcantly involved in parathyroid
hormone-dependent bone healing [15]. Although there are no
experimentalmodels for NK cell depletion in factures, an important
role of NK cells during bone repair has been implied when a high
level of interferon-gamma (IFN-g) was detected in the diaphyseal
regions of fractured femur in mice lacking T- and B-lymphocytes
[16]. Conversely, as shown in immune-compromised animalmodel,
bone marrow (BM) transplantation greatly enhanced the process of
bone healing [17]. In addition to experimental ﬁndings, immune-
compromised HIV patients can have delayed or non-union of
fractures [18]. Thus, both animal and human studies conﬁrmed the
critical importance of innate and adaptive immune cells.
While the outer layer of cortical bone carries theweight bearing
function, inner cancellous bone contains BM, a niche for different
cell types including bone progenitor cells and multipotential
stromal cells (MSCs). MSCs are classically identiﬁed as cells with
the adherence capacity, which also express surface molecules
CD90, CD73, CD105, but not hematopoietic lineage markers and
are able to differentiate into bone, fat and cartilage cells [19]. Beside
inﬂammatory cells and MSCs, two types of bone resident cells,
osteoclasts and osteoblasts also play critical roles during the
process of bone healing. Osteoclasts are large multinucleated cells
are differentiated from monocyte lineage cells and have a bone
degradation activity [20]. In contrast, the function of osteoblasts is
the bone formation and they are derived from MSC-differentiated
bone progenitor cells. Each of the immune cells has both distinctive
and common functions with each other or MSCs during the phases
of bone healing (Fig. 1). In this study, we review the vital role of the
immune cells and their interactions with bone cells and MSCs
(Fig. 2) and how this would affect the outcome of fracture healing.
Inflammatory phase
An early event of the injury of bone is the interruption of
blood supply and platelet aggregation with the release of
platelet-derived pro-inﬂammatory cytokines, Interlukin-6 (IL-
6), Interlukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-a).
These cytokines stimulate the homing of lymphocytes and
monocyte/macrophages into the fracture site. As shown in[(Fig._1)TD$FIG]
Fig. 1. The various roles of immune cells and MSCs during the phases of fracture healing. Early during inﬂammatory phase, both macrophages and MSCs can display
phagocytic functions. NK cells, T- and B-lymphocytes are contributed into osteoclastogenesis to clear cell debris. The effects of macrophages and NK cells can facilitate the
migration of MSCs. The licensing of MSCs can be mediated by cytokines released from NK cells, T- and B-lymphocytes. Then, licensed MSCs together with programmed
macrophages and T reg lymphocytes have late immunosuppressive effects to end the inﬂammatory phase. During the repair phase,MSCs carry the differentiation functions as
well as angiogenesis helped bymacrophages. Also, T-lymphocytes are involved in regulation of MSC osteogenicity. The conversion of soft cartilaginous callus into hard callus
is controlled bymacrophages, T- and B-lymphocytes. In the ﬁnal remodelling phase, osteoblast and osteoclast balance is regulated byMSCs andmacrophages and probably T-
lymphocytes (IL-17 and TNF-a effects).
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animal models, T- and B-lymphocytes are recruited at the
fracture site after 3 days of injury and then reduced in numbers
with the start of cartilaginous callus formation [14,21]. This
phase also involves formation of haematoma, which traps
inﬂammatory cells that further produce pro-inﬂammatory
inﬂammatory cytokines and growth factors. This haematoma
is crucial and its removal causes a defective bone healing
[22,23]. The main cellular events taking place during inﬂamma-
tory phase are presented below.
Clearing of damaged areas
Initially, neutrophils arrive to the fracture site as detected in a
rat model of fracture [24]. Neutrophils have an anti-septic effect
and clear the damaged cells and debris [25,26]. Other cells that
help to erode the damaged edges of bones are osteoclasts. Receptor
activator of nuclear factor kappa-B ligand (RANKL) that is produced
by activated T-lymphocytes and NK cells can induce the
differentiation of the osteoclasts from monocytes [27–29]. A role
[(Fig._2)TD$FIG]
Fig. 2. The key cellular interactions and soluble mediators during fracture healing. Immune cells, MSCs and osteoblasts and osteoclasts interact together during bone healing.
While NK cells, T- and B-lymphocytes can be involved in activation of immunosuppressive functions of MSCs via TNF-a, IL-17 and IFN-g, other cells like macrophages
stimulate the osteogenic differentiation of MSCs via BMPs and Oncostatin M. ILCs might have a role in stimulation of osteogenic capacity of MSCs via IL-22. However, only
licensed MSCs are able to suppress the functions of both innate and adaptive immune cells via multiple mechanisms such as IDO, PGE2, TSG6 and TGF-b. Also, MSCs can
differentiate into osteoblasts and chondroblasts, which form the soft callus. Immune cells; macrophages, T- and B-lymphocytes participate to promote the conversion of soft
callus into hard callus via action of MMPs, TNF-a and IL-17. The balance of the activity of osteoblast and osteoclasts are mainly regulated by macrophages and MSCs with
involvement of OPG and RANKL.
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of B-lymphocytes during inﬂammatory phase of bone healing has
been also linked to osteoclast formation [30]; but this role seem to
be tightly controlled as B-lymphocytes can also suppress the
osteoclast generation and enhance the apoptosis of osteoclasts
[31]. In addition to immune cells and osteoclasts, recruited MSCs
into fracture site could be involved in the clearing of dead tissues at
the fracture site by phagocytosis of apoptotic cells [32]. This is
associatedwith enhancement ofMSC osteogenesis and secretion of
interleukin (IL)-8, monocyte chemoattractant protein-1, and
RANTES that could stimulate the homing of T cells to the inﬂamed
area. Together, different cells can directly or via crosstalk work
early at the bone injury site to clear the debris and pave theway for
healing to start.
Migration of MSCs
MSCs widely exist within the skeleton in the periosteum, BM
and bone. Those MSCs that directly participate in the fracture
healing can originate from different sources. Whether localised at
the fracture site (periosteum and endosteum) or migrating to the
bone injury site, MSCs were shown to have a vital activity in
fracture healing [33–35].
It hasbeendemonstrated thatMSCsare recruited into the injured
bone site under the inﬂuence of an inﬂammatory chemokine,
Stromal Derived Factor-1 (SDF-1) [36]. The mechanism of SDF-
dependentmigrationofMSCs involves theactivationofalphaserine/
threonine-protein kinase (AKT) and extracellular-signal-regulated
kinases (ERK) signallingpathways [37,38]. InﬂammatoryTNF-a also
mediates the invasion of MSCs into the bone-healing site
[39]. Macrophage-derived chemokines, MCP-1 and monocyte
inﬂammatory protein 1 alpha (MIP-1a) have been also linked to
MSC migration to the bone healing site [40]. Recently, it has been
found that chemokine; CXCL7 that produced by NK cells enhances
MSCmigration [41]. Overall, immune cells such asmacrophages and
NK cells as well as inﬂammatory cytokines and chemokines can act
together to help the homing of MSCs into the fracture-healing site.
Preparation for the repair phase; licensing of MSCs
The term licensing is commonly used to describe the activation
of MSCs to perform immunosuppressive functions. A group of
cytokines that produced within inﬂammatory milieu are respon-
sible for the licensing of MSCs and can act alone e.g. IFN-g or in
combination [42]. IFN-g can trigger the proliferation and
immunomodulatory function of MSCs via the Kynurenine-depen-
dent mechanism [43]. Likewise, TNF-a induces the proliferation
and immunosuppressive function of MSCs using the NF-kb
pathway [44]. Thus, NK cells and T-lymphocytes are linked to the
licensing of MSCs as major sources of TNF-a that is highly
expressed during both inﬂammatory and repair phases [45]. To-
gether with IFN-g and TNF-a, MSCs that are activated by IL-1 can
perform immunosuppressive functions associated with the pro-
duction of prostaglandin 2 (PGE2) and IL-8 [46]. Furthermore, it
has been shown that IL-17 is another licensing cytokine that can
enhance the immunosuppressive functions of MSCs both in vivo
and in vitro [47]. In summary, multiple licensing cytokines help to
programmeMSCs towards immunosuppressive activity in order to
control the inﬂammatory phase of healing.
Other inﬂammatorymediators and cells follow thewave ofMSC
‘licencing’ cytokines to directly enhance the osteogenic potential of
MSCs. Toll-like receptors (TLRs) stimulate MSC migration and
osteogenic differentiation utilising NFk-b and PI3 kinase signalling
pathways [48]. Additionally, macrophages existing in the fractured
bone are a source of bone morphogenetic proteins (BMPs) and
Oncostatin M that enhance the proliferation and osteogenic
function of MSCs [49,50]. Furthermore, activated monocytes
induce the expression level of Cbfa1/Runx2 and alkaline phospha-
tase (ALP) by MSCs and hence drive the bone formation [51]. In
contrast, a conditioned media from CD4 T-lymphocytes and not
CD8 has been shown to increase the osteogenesis markers of MSCs
[52]. Furthermore, innate lymphocytes cells (ILCs) that produce
tissue reparative cytokines such as interleukin-22 (IL-22) [53–55]
also seem to induce the osteogenic activity of MSCs. Recently, an in
vitro study has shown that IL-22 can induce the osteogenic
capacity of licensed BM MSCs [56]. Likewise, once MSCs are
licensed, IL-17 induces osteogenesis by increase the expression of
osteogenic proteins in MSCs, Cbfa1/Runx2 and collagen [14]. In
conclusion, the inﬂammatory microenvironment delivers impor-
tant signals that help the preparation of MSCs, proliferation and
immunomodulation and then the osteogenesis.
Reduction of immune cell response and the end of inflammatory phase
The control of immune cell response is critical to reduce the
inﬂammation and aid the switch into repair phase. Interestingly,
the levels of TGF-b2 and TGF-b3 reach the peak at the end of
inﬂammation most likely to control the immune response and
ﬁnalise the inﬂammatory phase [57]. As mentioned above, MSCs
are licensed to exert their immunosuppressive role. MSCs can
induce the generation of anti-inﬂammatory CD4+CD25+Foxp3+ T
reg lymphocytes with the production of immunosuppressive
cytokine, IL-10 [58]. Beside its effect on T reg lymphocytes, MSCs
directly induce the apoptosis and suppress the proliferation and
functions of pro-inﬂammatory Th1 and Th17 subsets [59,60]. Fur-
thermore, MSCs can decrease the function and the migration of B-
lymphocytes via the down-regulation of the chemokine receptors;
CXCR4, CXCR5 and CCR7 [61]. In addition to adaptive immune cells,
MSCs are able to inhibit the proliferation, secretory and
cytotoxicity functions of cytokine-activated NK cells [62,63] as
well as inhibition of the differentiation functions of monocyte-
derived dendritic cells [64].
MSCs employ these immunosuppressive effects via different
soluble molecules including TGF-b, indoleamine 2,3-dioxygenase
(IDO), inducible Nitric oxide synthases (iNOS), PGE2, IL-1 receptor
antagonist and Tumour necrosis factor-inducible gene 6 (TSG6)
[65–68]. Recently, other mechanisms of MSC-dependent immu-
nomodulation have been described. It has been shown that MSC-
derived extracellular vesicles have a strong immunosuppressive
effect on T- and B-lymphocytes as well as NK cell functions
[69]. Furthermore, MSCs can programme macrophages to display
anti-inﬂammatory M2 phenotype that suppresses both innate and
adaptive immune responses via IL-10 and TGF-b dependent
mechanisms [70]. Collectively, MSCs, which licensed by inﬂam-
matory signals act in turn to suppress the inﬂammatory responses
of immune cells as a negative feedback mechanism. This
mechanism helps the ignition of repair phase of bone healing.
Nevertheless, the effects of some immune cells and cytokines
continue to have a role during the repair and remodelling phases.
Repair phase
The repair phase involves the differentiation ofMSCs into either
osteoblasts when the broken bone edges are immaculately aligned
(primary healing) [71] or chondroblasts that proliferate forming a
cartilaginous structure called soft callus (secondary healing). The
soft callus is then mineralised and converted into bone callus with
irregularly arranged (woven) bone, which is invaded by new blood
vessels in a process called endochondral ossiﬁcation. In addition to
the differentiation function, MSCs support new blood vessel
formation via metalloproteinase-dependent mechanisms [72].
Certain immune cells are known to participate in the repair
phase. Macrophages participate in the induction of angiogenesis
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and a substantial reduction in macrophages is associated with
impaired vascularisation and delayed formation of callus as
revealed in CCR2/ mice model [73]. Bone-lining macrophages
participate in the intramembranous bone healing as shown in
mousemodel of tibial fracture [74]. Furthermore,macrophages can
regulate MSC differentiation into osteoblasts, as mentioned in
previous sections [75]. Macrophages have been detected in
invading vessels throughout the ossiﬁcation of mouse long bones
[76] and they efﬁciently produce matrix metalloproteinases
(MMPs) to degrade the cartilage matrix [77,78]. These MMPs
have a central role in soft-to-hard callus switch [79–81] and any
dysregulation of these enzyme activities has been linked to the
fracture non-union [82]. The deposition of collagen type I is
another function for macrophages and this is associated with up
regulation of macrophage macrosialin protein [74]. The multi-
function of macrophages highlights their unique importance
during the repair phase of either primary healing or endochondral
ossiﬁcation.
Other immune cells also reappear during the mineralisation of
cartilaginous callus. This includes T- and B-lymphocytes that were
found to be located in a close contact with osteoblasts and
osteoclasts [83]. Both types of adaptive lymphocytes produce TNF-
a, which trigger the death of mature chondrocytes aiding the
transition from cartilage into bone [84,85]. Importantly, the effect
of TNF-a on chondrocytes involves up-regulation of MMPs and
angiopoietin coordinating both of angiogenesis and ossiﬁcation of
soft callus [86]. IL-17 is another cytokine that can affect the
conversion of soft callus into hard callus. IL-17 can inhibit the
chondrogenic differentiation of MSCs via the suppression of a key
chondrogenesis transcriptional factor, SRY-box 9 (SOX9) and its
activator cAMP-dependent protein kinase (PKA) [87]. Additionally,
an in vitro work showed that IL-17 also enhances the MSC
differentiation into osteoblasts [88]. This all indicates that adaptive
lymphocytes can actively participate in the endochondral ossiﬁ-
cation.
Several growth factors are needed to support bone healing
particularly during the repair phase including platelet-derived
growth factor (PDGF), TGF-b, Insulin-like growth Factor (IGF),
ﬁbroblast growth factor-1 (FGF-1) and BMPs that promote the
proliferation and the chondrogenic differentiation of MSCs as well
as deposition of collagen [49,89,90]. Overall, the conversion of soft
callus into hard callus is highly controlled by macrophages, T- and
B-lymphocytes and various cytokines and growth factors demon-
strating the continuation of immune-bone interactions even after
the end of the inﬂammation phase.
Remodelling phase
The remodelling of woven bone into normal lamellar bone is
related to the balance between osteoblast and osteoclast
functions. The osteoblast/osteoclast function is controlled by
MSCs, macrophages and cytokines such as TNF-a and IL-17. As
mentioned above, the osteoblast formation from MSCs is
inﬂuenced by various growth factors such as TGF-b family
members, BMPs and IGF [91]. However, MSCs have an inhibitory
effect on monocyte differentiation into osteoclast via the
production of Osteoprotegerin (OPG) [92]. In contrast, RANKL
and M-CSF secreted by osteoblasts can improve the survival and
the function of osteoclasts [93,94]. Macrophages seem to
maintain the bone forming/resorption balance by augmentation
of the osteoblast activity and as being the progenitors of
osteoclasts [95]. Osteal macrophages are also responsible for
coordinating the crosstalk between osteoclasts and osteoblasts
[96]. Together, MSCs and macrophages seem to have contrasting
effects on osteoclasts to maintain the balance during the
remodelling.
The role of IL-17 in the remodelling of hard callus indicates a
possible involvement of T-lymphocytes during this phase. The
downstream effect of IL-17 on the osteoblasts includes the up-
regulation of the osteogenic mediators, bone sialoprotein, collagen
and osteocalcin [14]. At the same time, IL-17 enhances the
expression of RANKL on MSCs enhancing the osteoclastogenesis
when co-cultured with peripheral blood mononuclear cells
(PBMCs) [97]. Another cytokine, TNF-a produced by MSCs and
osteoblasts during late phase of bone healing [45] can also
inﬂuence both osteoblasts and osteoclasts functions demonstrat-
ing its vital role in the remodelling phase [98,99]. Overall, speciﬁc
immune cells and mediators keep the bone healing process under
control till the end.
The uncontrolled immune cell response and defective bone
healing
Systemic inﬂammatory diseases and local sepsis at the bone
injury site are linked to complicated healing including non-union
[100]. MSCs extracted from non-union tissues have an impaired
proliferative capacity and function compared to healthy controls
[101–104]. Nevertheless, these non-union MSCs retain their
osteogenic differentiation when activated in vitro [103,105]. This
indicates that the healingmicroenvironment including the effect of
immune response could be the main biological player in fracture
non-union.
An exaggerated activation of neutrophils using oxygen free
radicals is associated with defective healing of bone fracture [106],
while an induced neutropenia in animal models of bone defects
shows an enhanced osteogenic repair [107]. Likewise, excessive
stimulation of macrophages with lipopolysaccharide can decrease
their production of BMP-2 causing a delayed bone healing
[108]. Additionally, within a chronic inﬂammatory milieu, mono-
cytes have a higher potential to differentiate into osteoclasts
through TNF-a dependentmechanism [109]. Excessively activated
NK cells could mediate cytotoxicity against allogeneic or autolo-
gous MSCs [62,110–113]. Both Activated T-lymphocytes and B-
lymphocytes are well known to release RANKL, which boosts
osteoclast differentiation from their progenitors and subsequently
provoke the bone lysis [94,114]. Totally, although critical at the
early phase of bone healing, excess activation of immune cells has a
strong link to defective bone formation.
Several studies have proven that inﬂammatory cytokines IFN-g
and TNF-a can block the osteogenic differentiation of MSCs
[115,116]. TNF-a also works to enhance the expression of Wnt
signalling pathway antagonist, Dickkopf-1 (DKK-1) that has an
inhibitory effect on the osteoblast formation [117] and inhibits
nephronectin, an extracellular matrix protein, which helps the
proliferation of osteoblasts [118]. Furthermore, TNF-a stimulates
the production of M-CSF by MSCs that in turn, induce the
differentiation of osteoclast progenitors [119]. Similarly, IFN-g has
a positive inﬂuence on the osteoclastogenesis [120]. Furthermore,
IL-1 and IL-17 has been linked to the bone loss within highly
inﬂammatory milieu [121,122]. Altogether, this shows that excess
or prolonged inﬂammation via immune cells or cytokines can be
involved in impaired bone healing. Although cytokines such as IFN-
g and TNF-a are key players for MSC licensing, they can exert a
negative effect on osteogenic differentiation of MSCs. Therefore, it
is vital to determine the exact timings and levels needed of these
cytokines to ensure the correct balance between their actions
favouring bone healing.
What is unknown?
Despite all the research advances in the osteoimmunology ﬁeld,
more knowledge about cellular interactions during bone healing
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still required. The immune cell-MSC cross talk is essential to
complete the inﬂammatory phase and to initiate the repair phase.
However, it is still remaining to reveal if there is a link between
MSCs and neutrophils as both cells can be detected early during the
inﬂammation. Furthermore, the in vitro studies indicate compli-
cated interactions between NK cells and MSCs, i.e. NK cells
functions can be suppressed by MSCs and NK cells can participate
in MSC licensing, but also can kill MSCs [62,63,110–113]. Thus,
further research is necessary to understand the biological
importance of these interactions NK cells during physiological
fracture healing and how this would affect the cell therapy. Also, it
will be interesting to locate and identify the functions of innate
immune cells, ILCs within healing bone tissues. Similarly, although
IL-17 are linked to regulation osteoblast and osteoclast activity
[123], Th17 cell location in the ﬁnal stage of the bone healing
remains to be investigated. Also, CD4 and CD8 T-lymphocytes
seem to have contrasting effects on bone healing. The impact of the
variable effects of these subsets on the MSC osteogenic capacity
and the exact molecular mechanisms underlying these effects and
the time of their participation are not clear yet. All this knowledge
will help signiﬁcantly to improve the therapeutic strategies of
complicated fractures.
Therapeutic implications
The use of cell-therapy for non-union of fractures is a promising
alternative to conventional bone autograft. According to the
diamond concept [12,124–127], the biological elements of these
therapies should involve MSCs and growth mediators including
those promoting the new vasculature formation. Whether MSCs
are delivered within concentrated or not-concentrated mononu-
clear bone marrow cells [128,129] or as culture-expanded pure
population and loaded on matrices [130] or injected subcutane-
ously [131], their therapeutic use still needs further optimisation.
The inﬂammation status could affect considerably the effective-
ness of the regenerative treatments at least in part via their effect
onMSCs [132]. Also, the revascularisation of bone graft or matrices
are vital to maintain the survival and function within the healing
milieu via supplying the nutrition, oxygen supply and regulatory
mediators.
Several studies, in whichMSCswere used for bone and cartilage
repair, have indicated that the failure of therapeutic effect of
allogeneic MSCs was associated with signs of activated immune
responses [115,133–135]. However, in other studies where the
allogeneic MSCs were loaded into scaffolds, an inﬂammatory
response was similar to that induced by autologous MSCs with
better outcomes [136–141]. This could be related to limited
accessibility of allogeneic MSCs to host immune cells. For
autologous MSCs, in vitro studies have shown that NK cells can
lyse autologousMSCs similar to allogeneicMSCs [142]. The NK-cell
mediated killing of autologous MSCs is related to the low
expression of HLA-I molecules and high expression of NK cell
activating ligands on the MSC surface [62,110–113]. Thus, it is
remaining to investigate if under certain conditions, this mecha-
nism could threaten the fate of the transplanted MSCs for fracture
healing. Overall, this clearly indicates how immune response and
inﬂammatory milieu can greatly affect the activities of both
allogeneic and autologous MSCs. Also, the choice of the interven-
tion therapy time in relation to inﬂammation status is an essential
challenge to be addressed.
The in vitro polarisation of macrophages into either pro-
inﬂammatory M1 or anti-inﬂammatory M2 that are also involved
in tissue repair and angiogenesis, becomes possible via differenti-
ation of peripheral blood monocytes utilising speciﬁc cytokines
[143,144]. Importantly, it has been shown that both subsets
together highly support the angiogenesis. This role is mediated via
M1 cells that produce the angiogenesis prompting factors, VEGF,
IL-8, bFGF and RANTES. Additionally, M2 cells have been proposed
to enhance the blood vessel fusion, vascular remodelling and
regulation ofM1 activity [145]. These ﬁndings had a great potential
to be applied in the regenerative bone therapies to fabricate
scaffolds that help to polarise macrophages and consequently
supporting blood vessel formation during bone healing [145]
together with promoting the proliferation and polarisation of bone
progenitors cells to achieve a completed healing process.
Conclusions
Bone healing constitutes a successive process with three phases
starting with critical inﬂammation; in which both innate and
adaptive immune cells as well as cells of macrophage-osteoclast
lineage help the removal of bone debris, antisepsis and preparation
of MSCs for next repair phase. In turn, licensed MSCs work to
control the inﬂammatory phase and differentiate directly into
osteoblasts or most commonly into chondroblasts forming soft
callus. During this repair phase, certain immune cells and
mediators play an important role to convert soft callus into hard
callus and formation of new blood vessels. Finally, bone remodel-
ling is mediated via interplay between osteoclasts and osteoblasts
under inﬂuence of MSCs, macrophages and probably Th17
lymphocytes. The excess activation of the immune mediators
can inhibit the osteogenic differentiation of MSCs. Thus a delicate
balance between the functions of immune cells, MSCs and bone
cells are critical for healthy bone healing. The therapeutic use of
MSCs for bone loss and fractures should consider enhancing the
bone forming capacity of MSCs as well as microenvironment
particularly the inﬂammation status. Additionally, a new genera-
tion of biomaterials is needed to help the delivery of the
appropriate type and concentration of growth factors/cytokines
enhancing both osteogenesis and angiogenesis. The developed
knowledge about details of cellular interactions during the bone
healing will help to improve the outcomes of MSC-based therapy
used for complicated bone healing.
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